Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
NEWARK, Calif., May 02, 2017 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first quarter fiscal year 2017 financial results on Tuesday, May 9, 2017, after the close of markets. The Company will host a conference call beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its results.
Participants can access the call by dialing (844) 839-0046 (United States) or (857) 270-6032 (International) referencing Conference ID 10761035. The conference call will also be available via a live webcast on the Investor Relations section of Depomed's website at http://www.depomed.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
